// App-Quantinova.ai

EP524 : PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Researchers

Presenter

  • Anthony R. Mato

Principal Investigators

  • Nirav N. Shah

  • Nicole Lamanna

  • Toby A. Eyre

  • Wojciech Jurczak

  • Jennifer A. Woyach

  • Ewa Lech-Maranda

  • William G. Wierda

  • David Lewis

  • Meghan C. Thompson

  • Denise Wang

  • Ming Yin

  • Minna Balbas

  • Binoj C. Nair

  • Edward Y. Zhu

  • Nora C. Ku

  • Catherine C. Coombs

Medical Centers

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Herbert Irving Comprehensive Cancer Center, New York, New York, United States

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Plymouth Hospitals NHS Trust - Derriford Hospital ,Plymouth,United Kingdom

  • Medical College of Wisconsin,Brookfield, Wisconsin,United States

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Loxo Oncology at Lilly,Stamford, CT,United St

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • University of North Carolina, Chapel Hill, North Carolina, United States

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center,Oxford,United Kingdom

Locations

  • Poland

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT03740529

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved